Ascendis Pharma A/S (ASND)
Nasdaq: ASND · Pharmaceutical Preparations · filing with the SEC since 2014
Who runs Ascendis Pharma A/S
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedOfficers reporting now
8
of 15 people with a filing in the last fifteen months
Directors reporting now
7
15 people on the record since 2026
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Bodenhoff Mads | SVP & PAO | Mar 2026 | Sep 9, 2026 | 1 · $800,000 |
| Smith Scott Thomas | EVP & Chief Financial Officer | Mar 2026 | Jun 2, 2026 | none |
| Jensen Flemming Steen | EVP & Product Supply and Quality | Mar 2026 | May 12, 2026 | 1 · $4.6M |
| Wu Jay Donovan | EVP & President US Market | Mar 2026 | Mar 18, 2026 | none |
| Jensen Michael Wolff | EVP, Chief Legal Officer | Mar 2026 | Mar 18, 2026 | none |
| Pedersen Anni Lotte Kirstine Sonderbjerg | EVP & Chief Admin Officer | Mar 2026 | Mar 18, 2026 | none |
| Shu Aimee | EVP & Chief Medical Officer | Mar 2026 | Mar 18, 2026 | none |
| Sprogoe Kennett | EVP & Head of Research & Product Development | Mar 2026 | Mar 18, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Bienaime Jean Jacques | director | Apr 2026 | Sep 28, 2026 | none |
| Holtug Lars | director | Mar 2026 | Sep 3, 2026 | 1 · $100,000 |
| Cha Albert | director | Mar 2026 | Mar 18, 2026 | none |
| Fairey William | director | Mar 2026 | Mar 18, 2026 | none |
| Imani Siham | director | Mar 2026 | Mar 18, 2026 | none |
| Mikkelsen Jan Moller | director | Mar 2026 | Mar 18, 2026 | none |
| Morrison Lisa | director | Mar 2026 | Mar 18, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.